
Claims

[Claim 1]

A crystal of an oxazole compound represented by formula (5)



(5)

wherein the crystal has peaks at diffraction angles 2θ(°) of 9.6±0.2, 12.6±0.2, 19.1±0.2, 21.2±0.2 and 22.8±0.2 in an X-ray powder diffraction pattern measured using CuKα characteristic X-rays.

[Claim 2]

The crystal according to claim 1, wherein the crystal further has a peak at diffraction angles 2θ(°) of 26.0±0.2 in the X-ray powder diffraction pattern measured using CuKα characteristic X-rays.

[Claim 3]

The crystal according to claim 2, wherein the crystal further has one or more peaks at one or more diffraction angles 2θ(°) selected from the group consisting of 10.4±0.2, 11.9±0.2, 15.0±0.2, 15.9±0.2, 19.7±0.2, 24.7±0.2, and 27.6±0.2 in the X-ray powder diffraction pattern measured using CuKα characteristic X-rays.

[Claim 4]

The crystal according to claim 1, wherein the crystal has infrared absorption bands at wavenumbers (cm^{-1}) of 3380±5, 2980±5, 1651±2, 1501±2, 1258±2, 1121±2, and 754±2 in an infrared absorption spectrum measured by a potassium bromide disk method.

[Claim 5]

The crystal according to claim 4, wherein the crystal has a melting point of 75 to 90°C.

[Claim 6]

A pharmaceutical composition comprising the crystal according to claim 5.

[Claim 7]

A pharmaceutical composition comprising the crystal according to claim 4.

[Claim 8]

The crystal according to claim 1, wherein the crystal has a melting point of 75 to 90°C.

[Claim 9]

A pharmaceutical composition comprising the crystal according to claim 8.

[Claim 10]

A pharmaceutical composition comprising the crystal according to claim 1.

[Claim 11]

The pharmaceutical composition according to claim 10, for use in the treatment of eczema or dermatitis.

[Claim 12]

The pharmaceutical composition according to claim 10, which is an ointment.